DRG Market Assessment reports

Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key acute lymphoblastic leukemia populations covering 171 countries and more…

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the progressive development and enlargement of fluid-filled cysts in the kidneys, accompanied by symptoms…

Chronic inducible urticaria (CIndU) encompasses various chronic urticaria subtypes caused by specific triggers. CIndU seems to be more resistant than chronic spontaneous urticaria (CSU) to standard…

Myasthenia gravis (MG) is a rare neuromuscular disorder caused by autoantibodies at the neuromuscular junction targeting—in most patients—acetylcholine receptors; it is characterized by muscle…

Levodopa-induced dyskinesia (LID) is a complication stemming from the long-term use of levodopa to treat Parkinson’s disease (PD); it causes abnormal involuntary movements. Surveyed neurologists…

The HIV therapy market is crowded with many approved antiretroviral therapies (ARVs). Growth in this market is being driven by the increasing acceptance of new, high-priced ARVs, particularly the…

Several effective anti-inflammatory agents and bronchodilators are available for controlling mild or moderate asthma. However, despite the availability of long-acting muscarinic antagonists (LAMAs…

Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder characterized by high blood pressure in the arteries of the lungs. It is a progressive condition marked by considerable…

Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the availability of LAMAs (e.g., Boehringer-…

With a drug-treated population of over 3.3 million in the United States, France, Germany, and the United Kingdom, the moderate to severe psoriasis market has been a lucrative space for drug…

Although the schizophrenia drug market is crowded, few, if any, effective therapies are available in the United States and Europe to treat the negative symptoms of schizophrenia (e.g., apathy,…